 Kathleen Packard
Concepts (187)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Students, Health Occupations | 2 | 2019 | 29 | 0.730 |
Why?
| | Education, Distance | 1 | 2019 | 43 | 0.630 |
Why?
| | Interprofessional Relations | 2 | 2019 | 277 | 0.620 |
Why?
| | Fish Oils | 1 | 2019 | 26 | 0.620 |
Why?
| | Simulation Training | 1 | 2019 | 82 | 0.590 |
Why?
| | Cardiovascular Agents | 2 | 2016 | 156 | 0.580 |
Why?
| | Fatty Acids, Omega-3 | 2 | 2019 | 138 | 0.580 |
Why?
| | Secondary Prevention | 3 | 2016 | 218 | 0.540 |
Why?
| | Medication Adherence | 3 | 2016 | 558 | 0.520 |
Why?
| | Patient Safety | 1 | 2019 | 287 | 0.510 |
Why?
| | Aspirin | 2 | 2016 | 380 | 0.510 |
Why?
| | Acute Coronary Syndrome | 3 | 2014 | 267 | 0.460 |
Why?
| | Rhabdomyolysis | 1 | 2014 | 22 | 0.440 |
Why?
| | Pharmacists | 2 | 2014 | 247 | 0.410 |
Why?
| | Coronary Artery Bypass | 3 | 2004 | 224 | 0.390 |
Why?
| | Medication Reconciliation | 1 | 2012 | 29 | 0.380 |
Why?
| | Antipsychotic Agents | 1 | 2014 | 195 | 0.380 |
Why?
| | Platelet Aggregation Inhibitors | 2 | 2014 | 442 | 0.380 |
Why?
| | Cardiac Rehabilitation | 1 | 2012 | 34 | 0.370 |
Why?
| | Professional Role | 2 | 2014 | 158 | 0.370 |
Why?
| | Coronary Disease | 2 | 2004 | 385 | 0.350 |
Why?
| | Atrial Fibrillation | 4 | 2011 | 376 | 0.320 |
Why?
| | Education, Pharmacy | 1 | 2010 | 119 | 0.300 |
Why?
| | Angiotensin Receptor Antagonists | 3 | 2010 | 89 | 0.280 |
Why?
| | Patient Care Team | 1 | 2012 | 605 | 0.260 |
Why?
| | Heart Failure | 3 | 2014 | 2150 | 0.260 |
Why?
| | Adrenergic beta-Antagonists | 2 | 2010 | 321 | 0.250 |
Why?
| | Coronary Artery Disease | 1 | 2012 | 679 | 0.240 |
Why?
| | Hospitalization | 2 | 2014 | 2070 | 0.240 |
Why?
| | Thrombosis | 2 | 2012 | 343 | 0.230 |
Why?
| | Cardiovascular Diseases | 1 | 2016 | 2004 | 0.230 |
Why?
| | Calcium Channel Blockers | 3 | 2010 | 161 | 0.230 |
Why?
| | Nail Diseases | 1 | 2004 | 6 | 0.220 |
Why?
| | Losartan | 1 | 2004 | 14 | 0.220 |
Why?
| | Cholesterol, HDL | 1 | 2005 | 205 | 0.220 |
Why?
| | Graft Occlusion, Vascular | 1 | 2004 | 41 | 0.210 |
Why?
| | Angiotensin II | 1 | 2004 | 95 | 0.210 |
Why?
| | Practice Guidelines as Topic | 2 | 2014 | 1501 | 0.210 |
Why?
| | Histamine | 1 | 2003 | 65 | 0.210 |
Why?
| | Diltiazem | 1 | 2003 | 28 | 0.210 |
Why?
| | Gemfibrozil | 1 | 2002 | 11 | 0.200 |
Why?
| | Fenofibrate | 1 | 2002 | 31 | 0.200 |
Why?
| | Polyuria | 1 | 2002 | 2 | 0.200 |
Why?
| | Th1 Cells | 1 | 2003 | 138 | 0.200 |
Why?
| | Catheters, Indwelling | 1 | 2003 | 80 | 0.200 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 2 | 2010 | 198 | 0.200 |
Why?
| | Propanolamines | 1 | 2003 | 97 | 0.200 |
Why?
| | Bronchial Diseases | 1 | 2002 | 38 | 0.190 |
Why?
| | Piperazines | 3 | 2014 | 342 | 0.190 |
Why?
| | Th2 Cells | 1 | 2003 | 171 | 0.190 |
Why?
| | Hyperlipidemias | 1 | 2002 | 126 | 0.190 |
Why?
| | Anti-Obesity Agents | 1 | 2002 | 53 | 0.190 |
Why?
| | Lactones | 1 | 2002 | 58 | 0.190 |
Why?
| | Edema | 1 | 2002 | 124 | 0.190 |
Why?
| | Constipation | 1 | 2002 | 88 | 0.180 |
Why?
| | Tissue Plasminogen Activator | 1 | 2003 | 222 | 0.180 |
Why?
| | Fibrinolytic Agents | 1 | 2003 | 263 | 0.170 |
Why?
| | Students, Pharmacy | 2 | 2012 | 96 | 0.170 |
Why?
| | Smoking Cessation | 1 | 2004 | 407 | 0.160 |
Why?
| | Nursing Evaluation Research | 1 | 2019 | 45 | 0.160 |
Why?
| | Recombinant Proteins | 1 | 2003 | 1304 | 0.160 |
Why?
| | Nursing Education Research | 1 | 2019 | 39 | 0.160 |
Why?
| | Humans | 26 | 2019 | 129650 | 0.160 |
Why?
| | Asthma | 2 | 2003 | 2230 | 0.160 |
Why?
| | Education, Nursing, Graduate | 1 | 2019 | 33 | 0.160 |
Why?
| | Renal Dialysis | 1 | 2003 | 423 | 0.150 |
Why?
| | Eicosapentaenoic Acid | 1 | 2019 | 36 | 0.150 |
Why?
| | Drug Interactions | 4 | 2015 | 394 | 0.150 |
Why?
| | Endothelium, Vascular | 1 | 2005 | 901 | 0.150 |
Why?
| | Medical Errors | 1 | 2019 | 104 | 0.150 |
Why?
| | Docosahexaenoic Acids | 1 | 2019 | 83 | 0.150 |
Why?
| | Students, Nursing | 1 | 2019 | 72 | 0.150 |
Why?
| | Kidney Failure, Chronic | 1 | 2003 | 547 | 0.140 |
Why?
| | Smoking | 1 | 2004 | 1501 | 0.130 |
Why?
| | Perception | 1 | 2019 | 340 | 0.130 |
Why?
| | Prasugrel Hydrochloride | 2 | 2014 | 22 | 0.120 |
Why?
| | Male | 13 | 2019 | 63681 | 0.120 |
Why?
| | Cytokines | 1 | 2003 | 2017 | 0.120 |
Why?
| | Thiophenes | 2 | 2014 | 118 | 0.120 |
Why?
| | Treatment Outcome | 6 | 2016 | 10230 | 0.120 |
Why?
| | Postoperative Complications | 2 | 2004 | 2483 | 0.120 |
Why?
| | Pharmaceutical Services | 2 | 2014 | 81 | 0.120 |
Why?
| | Qualitative Research | 2 | 2019 | 1235 | 0.110 |
Why?
| | Dietary Supplements | 1 | 2019 | 534 | 0.110 |
Why?
| | Female | 13 | 2019 | 68776 | 0.110 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2002 | 985 | 0.110 |
Why?
| | Cardiovascular System | 1 | 2015 | 137 | 0.110 |
Why?
| | Acetanilides | 1 | 2013 | 11 | 0.110 |
Why?
| | Sodium Channel Blockers | 1 | 2013 | 24 | 0.110 |
Why?
| | Adenosine | 2 | 2014 | 227 | 0.110 |
Why?
| | Antidepressive Agents | 1 | 2015 | 228 | 0.110 |
Why?
| | Angina Pectoris | 1 | 2013 | 67 | 0.110 |
Why?
| | Recurrence | 1 | 2016 | 1007 | 0.110 |
Why?
| | United States | 4 | 2019 | 13903 | 0.110 |
Why?
| | Clinical Trials as Topic | 2 | 2012 | 1004 | 0.100 |
Why?
| | Body Temperature | 1 | 2014 | 212 | 0.100 |
Why?
| | Risk Factors | 3 | 2016 | 9765 | 0.100 |
Why?
| | Affect | 1 | 2015 | 286 | 0.100 |
Why?
| | Aged | 8 | 2014 | 22103 | 0.100 |
Why?
| | Health Resources | 1 | 2013 | 114 | 0.100 |
Why?
| | Interdisciplinary Studies | 1 | 2012 | 29 | 0.100 |
Why?
| | Health Occupations | 1 | 2012 | 30 | 0.100 |
Why?
| | Imines | 1 | 2012 | 8 | 0.100 |
Why?
| | Cardiac Surgical Procedures | 2 | 2010 | 499 | 0.100 |
Why?
| | Heart Diseases | 1 | 2015 | 350 | 0.100 |
Why?
| | Professional Competence | 1 | 2012 | 94 | 0.090 |
Why?
| | Hemorrhage | 2 | 2014 | 678 | 0.090 |
Why?
| | Medication Errors | 1 | 2012 | 95 | 0.090 |
Why?
| | Drug Therapy, Combination | 1 | 2014 | 1040 | 0.090 |
Why?
| | Hospitals, Private | 1 | 2010 | 12 | 0.090 |
Why?
| | Cooperative Behavior | 1 | 2012 | 433 | 0.080 |
Why?
| | Sotalol | 2 | 2010 | 6 | 0.080 |
Why?
| | Amiodarone | 2 | 2010 | 24 | 0.080 |
Why?
| | Intracranial Hemorrhages | 1 | 2009 | 80 | 0.080 |
Why?
| | California | 1 | 2010 | 401 | 0.080 |
Why?
| | Warfarin | 1 | 2009 | 147 | 0.080 |
Why?
| | Pyridines | 1 | 2012 | 478 | 0.070 |
Why?
| | Educational Measurement | 1 | 2010 | 262 | 0.070 |
Why?
| | Postoperative Period | 2 | 2010 | 329 | 0.070 |
Why?
| | Middle Aged | 6 | 2014 | 31154 | 0.070 |
Why?
| | Anticoagulants | 1 | 2011 | 637 | 0.070 |
Why?
| | Adult | 5 | 2014 | 35576 | 0.070 |
Why?
| | Amlodipine | 1 | 2006 | 10 | 0.070 |
Why?
| | Depression | 1 | 2015 | 1307 | 0.070 |
Why?
| | Antihypertensive Agents | 2 | 2010 | 485 | 0.070 |
Why?
| | Tetrazoles | 1 | 2006 | 38 | 0.060 |
Why?
| | Evidence-Based Medicine | 1 | 2010 | 718 | 0.060 |
Why?
| | Hypertension | 2 | 2006 | 1242 | 0.060 |
Why?
| | Valine | 1 | 2006 | 81 | 0.060 |
Why?
| | Patient Education as Topic | 1 | 2010 | 743 | 0.060 |
Why?
| | Influenza Vaccines | 1 | 2009 | 532 | 0.060 |
Why?
| | Hyperemia | 1 | 2005 | 48 | 0.060 |
Why?
| | India | 1 | 2005 | 170 | 0.060 |
Why?
| | Cross-Over Studies | 2 | 2006 | 521 | 0.060 |
Why?
| | Toes | 1 | 2004 | 15 | 0.060 |
Why?
| | Anti-Arrhythmia Agents | 1 | 2004 | 111 | 0.060 |
Why?
| | Fingers | 1 | 2004 | 86 | 0.050 |
Why?
| | Brachial Artery | 1 | 2005 | 192 | 0.050 |
Why?
| | Histamine H1 Antagonists | 1 | 2003 | 29 | 0.050 |
Why?
| | Probability | 1 | 2004 | 306 | 0.050 |
Why?
| | Vascular Patency | 1 | 2003 | 102 | 0.050 |
Why?
| | Cholesterol, LDL | 1 | 2005 | 358 | 0.050 |
Why?
| | Receptors, Angiotensin | 1 | 2002 | 12 | 0.050 |
Why?
| | Equipment Failure | 1 | 2003 | 107 | 0.050 |
Why?
| | Triglycerides | 1 | 2005 | 527 | 0.050 |
Why?
| | Medical Records | 1 | 2003 | 171 | 0.050 |
Why?
| | Thrombolytic Therapy | 1 | 2003 | 137 | 0.050 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2010 | 1279 | 0.050 |
Why?
| | Renin-Angiotensin System | 1 | 2002 | 82 | 0.050 |
Why?
| | Chi-Square Distribution | 1 | 2002 | 516 | 0.050 |
Why?
| | Vasodilation | 1 | 2005 | 476 | 0.050 |
Why?
| | Behavior Therapy | 1 | 2004 | 241 | 0.050 |
Why?
| | Prospective Studies | 2 | 2004 | 7133 | 0.050 |
Why?
| | Disease-Free Survival | 1 | 2003 | 648 | 0.050 |
Why?
| | Graft Survival | 1 | 2004 | 512 | 0.040 |
Why?
| | Multivariate Analysis | 1 | 2005 | 1502 | 0.040 |
Why?
| | Risk Assessment | 2 | 2015 | 3240 | 0.040 |
Why?
| | Counseling | 1 | 2004 | 385 | 0.040 |
Why?
| | Follow-Up Studies | 2 | 2013 | 4897 | 0.040 |
Why?
| | Graft Rejection | 1 | 2004 | 598 | 0.040 |
Why?
| | Sex Factors | 1 | 2005 | 1968 | 0.040 |
Why?
| | Retrospective Studies | 3 | 2013 | 14518 | 0.040 |
Why?
| | Polypharmacy | 1 | 2015 | 84 | 0.030 |
Why?
| | Young Adult | 1 | 2010 | 12426 | 0.030 |
Why?
| | Ranolazine | 1 | 2013 | 25 | 0.030 |
Why?
| | Purinergic P2Y Receptor Antagonists | 1 | 2014 | 66 | 0.030 |
Why?
| | Time Factors | 1 | 2003 | 6556 | 0.020 |
Why?
| | Patient Selection | 1 | 2015 | 663 | 0.020 |
Why?
| | Risk | 1 | 2014 | 854 | 0.020 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2011 | 72 | 0.020 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2011 | 93 | 0.020 |
Why?
| | Double-Blind Method | 2 | 2006 | 1876 | 0.020 |
Why?
| | Comorbidity | 1 | 2015 | 1547 | 0.020 |
Why?
| | Digoxin | 1 | 2010 | 27 | 0.020 |
Why?
| | Food-Drug Interactions | 1 | 2009 | 9 | 0.020 |
Why?
| | Animals | 1 | 2012 | 35361 | 0.020 |
Why?
| | Signal Transduction | 1 | 2003 | 4925 | 0.020 |
Why?
| | Hospital Costs | 1 | 2010 | 114 | 0.020 |
Why?
| | Acetylcysteine | 1 | 2010 | 146 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2014 | 2012 | 0.020 |
Why?
| | Percutaneous Coronary Intervention | 1 | 2014 | 467 | 0.020 |
Why?
| | Myocardial Infarction | 1 | 2014 | 1022 | 0.020 |
Why?
| | Valsartan | 1 | 2006 | 27 | 0.020 |
Why?
| | Angiotensin II Type 1 Receptor Blockers | 1 | 2006 | 36 | 0.020 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2010 | 430 | 0.020 |
Why?
| | Heart Valve Prosthesis Implantation | 1 | 2004 | 177 | 0.010 |
Why?
| | Blood Pressure | 1 | 2006 | 1736 | 0.010 |
Why?
|
|
Packard's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|